{"id":7532,"date":"2022-02-01T19:27:04","date_gmt":"2022-02-01T19:27:04","guid":{"rendered":"http:\/\/wordpress.p607267.webspaceconfig.de\/news\/"},"modified":"2022-02-07T09:52:11","modified_gmt":"2022-02-07T09:52:11","slug":"news","status":"publish","type":"page","link":"https:\/\/www.sanochemia.com\/en\/news\/","title":{"rendered":"News"},"content":{"rendered":"

[vc_row padding_top_multiplier=”custom” padding_bottom_multiplier=”2x” rc_heading_color=”white” rc_link_color=”white” rc_link_hover_color=”white” rc_bg_type=”color” padding_top=”17%” rc_font_color=”#ffffff” rc_bg_color=”#004189″][vc_column width=”1\/6″ vertical_content_position=”middle” tablet_width=”1-12″ tablet_sm_width=”hide” mobile_width=”hide”][\/vc_column][vc_column width=”5\/6″ vertical_content_position=”middle” tablet_width=”11-12″ tablet_sm_width=”1″]

Recent<\/span><\/h1>[\/vc_column][\/vc_row][vc_row padding_top_multiplier=”” padding_bottom_multiplier=”” separator_top=”line-separator” separator_top_size=”180px” separator_top_color=”#004189″ separator_top_hide=”mobile”][vc_column content_width=”75″ horizontal_content_position=”center” tablet_sm_content_width=”90″ mobile_content_width=”100″]
\r\n\t
\r\n\t\t
<\/div>\r\n\r\n\t
\r\n\t\t
\r\n\t\t\t
\r\n\t
\r\n\t\t
\r\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\tSanochemia submits Marketing Authorization Application for USPIO Ferumoxtran in selected EU Member States<\/span><\/a>\r\n\t\t\t\t
\"\"<\/div><\/div>\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\t\t\t

Sanochemia submits Marketing Authorization Application for USPIO Ferumoxtran in selected EU Member States<\/span><\/h2><\/a>\t\t\t\t
\r\n\t\t\t\t\t

Sanochemia submits a marketing authorization application (MAA) for Ferumoxtran under the decentralized procedure. The USPIO-based MRI contrast agent is intended for the detection and characterization of lymph node metastases in prostate cancer patients.\n<\/p>Read more<\/span>\t\t\t\t\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t<\/svg>\r\n\t\t\t<\/a>\t\t\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t\t\r\n\t\t\t\r\n\t\t\t

\r\n\t\t
\r\n\t\t\t
\r\n\t
\r\n\t\t
\r\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\tSanochemia receives ALC Inclusion Award<\/span><\/a>\r\n\t\t\t\t
\"\"<\/div><\/div>\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\t\t\t

Sanochemia receives ALC Inclusion Award<\/span><\/h2><\/a>\t\t\t\t
\r\n\t\t\t\t\t

In October 2025, Sanochemia Pharmazeutika was honored with the Austrian Leading Companies (ALC) Inclusion Award. This recognition highlights the company\u2019s longstanding commitment to fostering diversity, equal opportunities, and accessibility in the workplace.\n<\/p>Read more<\/span>\t\t\t\t\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t<\/svg>\r\n\t\t\t<\/a>\t\t\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t\t\r\n\t\t\t\r\n\t\t\t

\r\n\t\t
\r\n\t\t\t
\r\n\t
\r\n\t\t
\r\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\tSanochemia\/SPL: Investigational Iron-Based MRI Contrast Agent Meets Also Secondary Endpoints in Phase III<\/span><\/a>\r\n\t\t\t\t
\"\"<\/div><\/div>\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\t\t\t

Sanochemia\/SPL: Investigational Iron-Based MRI Contrast Agent Meets Also Secondary Endpoints in Phase III<\/span><\/h2><\/a>\t\t\t\t
\r\n\t\t\t\t\t

The multicentric prospective PROSTAPROGRESS study on Ferumoxtran confirmed to meet also secondary endpoints. Post-hoc analysis showed elevated sensitivity and specificity data for metastatic lymph node lesions at levels surpassing the levels of current technologies.\n<\/p>Read more<\/span>\t\t\t\t\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t<\/svg>\r\n\t\t\t<\/a>\t\t\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t\t\r\n\t\t\t\r\n\t\t\t

\r\n\t\t
\r\n\t\t\t
\r\n\t
\r\n\t\t
\r\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\tSanochemia\/SPL: Investigational Iron-Based MRI Contrast Agent Meets Primary Endpoints in Pivotal Phase III Study<\/span><\/a>\r\n\t\t\t\t
\"Signing<\/div><\/div>\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\t\t\t

Sanochemia\/SPL: Investigational Iron-Based MRI Contrast Agent Meets Primary Endpoints in Pivotal Phase III Study<\/span><\/h2><\/a>\t\t\t\t
\r\n\t\t\t\t\t

Neufeld, Austria, February 25th, 2025 \u2013 Sanochemia Pharmazeutika today announced positive headline results of the pivotal phase III study PROSTAPROGRESS on Ferumoxtran (EudraCT 2018-004310-18), performed by SPL Medical B.V. (Nijmegen,…<\/p>Read more<\/span>\t\t\t\t\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t<\/svg>\r\n\t\t\t<\/a>\t\t\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t\t\r\n\t\t\t\r\n\t\t\t

\r\n\t\t
\r\n\t\t\t
\r\n\t
\r\n\t\t
\r\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\tSanochemia aiming to expand access to liver-specific contrast agent in Europe<\/span><\/a>\r\n\t\t\t\t
\"\"<\/div><\/div>\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\t\t\t

Sanochemia aiming to expand access to liver-specific contrast agent in Europe<\/span><\/h2><\/a>\t\t\t\t
\r\n\t\t\t\t\t

Sanochemia Pharmazeutika continues to strengthen its position in medical imaging with the submission of an application for its liver-specific contrast agent in multiple European countries.\n<\/p>Read more<\/span>\t\t\t\t\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t<\/svg>\r\n\t\t\t<\/a>\t\t\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t\t\r\n\t\t\t\r\n\t\t\t

\r\n\t\t
\r\n\t\t\t
\r\n\t
\r\n\t\t
\r\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\tNew record on order volumes and capacity expansion at Sanochemia Pharmazeutika<\/span><\/a>\r\n\t\t\t\t
\"\"<\/div><\/div>\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\t\t\t

New record on order volumes and capacity expansion at Sanochemia Pharmazeutika<\/span><\/h2><\/a>\t\t\t\t
\r\n\t\t\t\t\t

The registration initiative launched by Sanochemia Pharmazeutika in 2021, together with the continuously increasing market demand, has led to a record volume of orders. \n<\/p>Read more<\/span>\t\t\t\t\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t<\/svg>\r\n\t\t\t<\/a>\t\t\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t\t\r\n\t\t\t\r\n\t\t\t

\r\n\t\t
\r\n\t\t\t
\r\n\t
\r\n\t\t
\r\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\tNew contrast agent aims to detect the smallest lymphatic metastases in prostate cancer<\/span><\/a>\r\n\t\t\t\t
\"Signing<\/div><\/div>\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\t\t\t

New contrast agent aims to detect the smallest lymphatic metastases in prostate cancer<\/span><\/h2><\/a>\t\t\t\t
\r\n\t\t\t\t\t

Sanochemia Pharmazeutika secures exclusive licensing rights to a new MRI contrast agent based on ferumoxtran, that is in an advanced pivotal trial in clinical phase III and may be used to detect the smallest lymph node metastases in prostate cancer patients. The product is already deployed in the Netherlands within an authorized Named-Patient-Use-Program (Artsenverklaring). \n<\/p>Read more<\/span>\t\t\t\t\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t<\/svg>\r\n\t\t\t<\/a>\t\t\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t\t\r\n\t\t\t\r\n\t\t\t

\r\n\t\t
\r\n\t\t\t
\r\n\t
\r\n\t\t
\r\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\tSanochemia initiates global roll-out of an Iron-based MRI contrast agent for the liver<\/span><\/a>\r\n\t\t\t\t
\"\"<\/div><\/div>\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\t\t\t

Sanochemia initiates global roll-out of an Iron-based MRI contrast agent for the liver<\/span><\/h2><\/a>\t\t\t\t
\r\n\t\t\t\t\t

Sanochemia Pharmazeutika is strengthening its position in the field of medical imaging with an exclusive product license for a MRI contrast agent based on iron-containing nanoparticles under the brand name Resotran\u00ae.\n<\/p>Read more<\/span>\t\t\t\t\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t<\/svg>\r\n\t\t\t<\/a>\t\t\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t\t\r\n\t\t\t\r\n\t\t\t

\r\n\t\t
\r\n\t\t\t
\r\n\t
\r\n\t\t
\r\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\tEmbracing Sustainability with brand new PV Facility<\/span><\/a>\r\n\t\t\t\t
\"Photovoltaik<\/div><\/div>\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\t\t\t

Embracing Sustainability with brand new PV Facility<\/span><\/h2><\/a>\t\t\t\t
\r\n\t\t\t\t\t

Sanochemia Pharmazeutika is taking the green transition as an opportunity and takes a leap towards sustainability with a new photovoltaic (PV) facility.\n<\/p>Read more<\/span>\t\t\t\t\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t<\/svg>\r\n\t\t\t<\/a>\t\t\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t\t\r\n\t\t\t\r\n\t\t\t

\r\n\t\t
\r\n\t\t\t
\r\n\t
\r\n\t\t
\r\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\tApprentice award for special achievements<\/span><\/a>\r\n\t\t\t\t
\"\"<\/div><\/div>\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\t\t\t

Apprentice award for special achievements<\/span><\/h2><\/a>\t\t\t\t
\r\n\t\t\t\t\t

For Sanochemia, joint development with employees is an important cornerstone of entrepreneurial activities. It is therefore particularly gratifying that some of Sanochemia's apprentices were honored for their special achievements: In…<\/p>Read more<\/span>\t\t\t\t\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t\t<\/polygon>\r\n\t\t\t\t<\/svg>\r\n\t\t\t<\/a>\t\t\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t<\/div>\r\n\t\t\t<\/div>\r\n\t\t\t\r\n\t\t\t\r\n\t\t\t